{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:27:02Z","timestamp":1769120822051,"version":"3.49.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.amjmed.2016.09.012","type":"journal-article","created":{"date-parts":[[2016,10,16]],"date-time":"2016-10-16T16:59:16Z","timestamp":1476637156000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice"],"prefix":"10.1016","volume":"130","author":[{"given":"Micha\u0142","family":"Mazurek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2016.09.012_bib1","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1540-8167.2011.02257.x","article-title":"Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score\u00a0= 0 in a community-based cohort study","volume":"23","author":"Taillandier","year":"2012","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2016.09.012_bib3","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1001\/jama.2015.4369","article-title":"Stroke prevention in atrial fibrillation: a systematic review","volume":"313","author":"Lip","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2016.09.012_bib4","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1160\/TH15-07-0565","article-title":"Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy","volume":"114","author":"Lip","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2016.09.012_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib6","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1161\/CIRCULATIONAHA.115.016713","article-title":"Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated?: yes: even 1 stroke risk factor confers a real risk of stroke","volume":"133","author":"Lip","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.09.012_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.09.012_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.09.012_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.09.012_bib10","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2016.09.012_bib11","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2016.09.012_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2014.10.052","article-title":"Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1","volume":"65","author":"Friberg","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib13","doi-asserted-by":"crossref","first-page":"h5876","DOI":"10.1136\/bmj.h5876","article-title":"Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study","volume":"351","author":"Staerk","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2016.09.012_bib14","first-page":"794","article-title":"EUR Observational research programme: atrial fibrillation general registry pilot phase","volume":"34","author":"Lip","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib15","first-page":"260","article-title":"Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry","volume":"61","author":"Akao","year":"2013","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib16","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1253\/circj.CJ-14-0344","article-title":"Inappropriate use of oral anticoagulants for patients with atrial fibrillation","volume":"78","author":"Akao","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ahj.2013.12.006","article-title":"Design and rationale of global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation","volume":"167","author":"Huisman","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2011.09.011","article-title":"International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)","volume":"163","author":"Kakkar","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ahj.2011.07.001","article-title":"Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF","volume":"162","author":"Piccini","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib20","first-page":"95","article-title":"Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation-The J-RHYTHM Registry study design","volume":"57","author":"Atarashi","year":"2011","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jacc.2010.03.043","article-title":"Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program","volume":"56","author":"Chan","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCOUTCOMES.114.001263","article-title":"Get with the guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation","volume":"7","author":"Lewis","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjmed.2016.09.012_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/heartjnl-2011-300550","article-title":"Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry","volume":"98","author":"Steg","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.amjmed.2016.09.012_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.acvd.2014.01.001","article-title":"Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey","volume":"107","author":"Gamra","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.amjmed.2016.09.012_bib25","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib26","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1093\/eurheartj\/ehl015","article-title":"Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation","volume":"27","author":"Nieuwlaat","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib27","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1053\/euhj.2001.2983","article-title":"ACC\/AHA\/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guide","volume":"22","author":"Fuster","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1445-5994.2001.00071.x","article-title":"Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice","volume":"31","author":"Jackson","year":"2001","journal-title":"Intern Med J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.annemergmed.2004.01.010","article-title":"Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 study","volume":"44","author":"Laguna","year":"2004","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.amjmed.2016.09.012_bib30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ahj.2007.03.008","article-title":"Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation","volume":"153","author":"Nieuwlaat","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehn101","article-title":"Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?","volume":"29","author":"Nieuwlaat","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2006.10.047","article-title":"Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation","volume":"49","author":"Dagres","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2016.09.012_bib34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.recesp.2011.04.005","article-title":"The improved but unfinished business of stroke risk stratification in atrial fibrillation","volume":"64","author":"Banerjee","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib35","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2013developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2016.09.012_bib36","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.09.012_bib37","unstructured":"Atrial fibrillation: the management of atrial fibrillation. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25340239. Accessed December 12,\u00a02015."},{"key":"10.1016\/j.amjmed.2016.09.012_bib38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A\u00a0prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2016.09.012_bib39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.amjmed.2013.12.022","article-title":"\u201cReal-world\u201d antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey","volume":"127","author":"Lip","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2016.09.012_bib40","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/europace\/euv269","article-title":"Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry","volume":"17","author":"Lip","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2016.09.012_bib41","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1093\/eurheartj\/ehu374","article-title":"Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib42","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/eurheartj\/ehn139","article-title":"Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation","volume":"29","author":"Nieuwlaat","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib43","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.amjcard.2011.06.017","article-title":"Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program)","volume":"108","author":"Chan","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib44","doi-asserted-by":"crossref","first-page":"654.e1","DOI":"10.1016\/j.amjmed.2014.11.035","article-title":"Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation","volume":"128","author":"Hsu","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2016.09.012_bib45","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamainternmed.2015.0920","article-title":"Oral anticoagulant prescription in patients with atrial fibrillation and a low risk of thromboembolism: insights from the NCDR PINNACLE Registry","volume":"175","author":"Hsu","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjmed.2016.09.012_bib46","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.hrthm.2014.04.021","article-title":"Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong","volume":"11","author":"Siu","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjmed.2016.09.012_bib47","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.10.006","article-title":"Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China National Stroke Registry","volume":"23","author":"Wang","year":"2014","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.amjmed.2016.09.012_bib48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/STROKEAHA.115.011833","article-title":"Use of warfarin at discharge among acute ischemic stroke patients with nonvalvular atrial fibrillation in China","volume":"47","author":"Yang","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2016.09.012_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3988\/jcn.2016.12.1.34","article-title":"Adherence to guidelines for antithrombotic therapy in patients with atrial fibrillation according to CHADS2 Score before and after stroke: a multicenter observational study from Korea","volume":"12","author":"Kim","year":"2016","journal-title":"J\u00a0Clin Neurol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib50","doi-asserted-by":"crossref","first-page":"e0125257","DOI":"10.1371\/journal.pone.0125257","article-title":"Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2016.09.012_bib51","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/pace.12445","article-title":"Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2 DS2 -VASc score of 1","volume":"37","author":"Huang","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib52","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/STROKEAHA.112.667865","article-title":"Atrial fibrillation and the risk of ischemic stroke: does it still matter in patients with a CHA2DS2-VASc score of 0 or 1?","volume":"43","author":"Chao","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2016.09.012_bib53","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/CIRCEP.113.000858","article-title":"Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation","volume":"7","author":"Siu","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib54","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/pace.12443","article-title":"Baseline characteristics and 1-year follow-up of Chinese atrial fibrillation patients according to age: a registry study","volume":"37","author":"Chen","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib55","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1253\/circj.CJ-11-0427","article-title":"Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. - Subanalysis of the J-RHYTHM Registry-","volume":"75","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib56","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1253\/circj.CJ-10-1119","article-title":"Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry","volume":"75","author":"Atarashi","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib57","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1253\/circj.CJ-13-0290","article-title":"Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry","volume":"77","author":"Inoue","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib58","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/europace\/euw073","article-title":"Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort","volume":"18","author":"Huisman","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2016.09.012_bib59","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjmed.2015.07.013","article-title":"Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, phase II","volume":"128","author":"Huisman","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2016.09.012_bib60","doi-asserted-by":"crossref","first-page":"e63479","DOI":"10.1371\/journal.pone.0063479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry","volume":"8","author":"Kakkar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2016.09.012_bib61","unstructured":"Kakkar AK (2015, August). Anticoagulation and AF: real life data from the GARFIELD-AF registry. In: Symposium Conducted at ESC Congress 2015, London, United Kingdom. Available at: http:\/\/congress365.escardio.org\/Session\/16231#.WBO9MMm_Gy4."},{"key":"10.1016\/j.amjmed.2016.09.012_bib62","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/eurheartj\/ehw233","article-title":"Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"37","author":"Bassand","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: Primary results of the PREvention of thromboembolic events-European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2016.09.012_bib64","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/CIRCULATIONAHA.114.008643","article-title":"Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"129","author":"Steinberg","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.09.012_bib65","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1136\/heartjnl-2014-305486","article-title":"Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe","volume":"100","author":"De Caterina","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.amjmed.2016.09.012_bib66","doi-asserted-by":"crossref","first-page":"e000110","DOI":"10.1161\/JAHA.113.000110","article-title":"Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry","volume":"2","author":"Fosbol","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.amjmed.2016.09.012_bib67","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/europace\/euv068","article-title":"Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation","volume":"17","author":"Camm","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2016.09.012_bib68","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ahj.2011.07.019","article-title":"Improvement in use of anticoagulation therapy in patients with ischemic stroke: results from Get With The Guidelines-Stroke","volume":"162","author":"Lewis","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib69","doi-asserted-by":"crossref","first-page":"e0142394","DOI":"10.1371\/journal.pone.0142394","article-title":"Predictors for stroke and death in non-anticoagulated Asian patients with atrial fibrillation: the Fushimi AF Registry","volume":"10","author":"Hamatani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2016.09.012_bib70","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1253\/circj.CJ-14-1245","article-title":"Low body weight is associated with the incidence of stroke in atrial fibrillation patients - insight from the Fushimi AF Registry","volume":"79","author":"Yamashita","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib71","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1253\/circj.CJ-14-1131","article-title":"Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy\u2013pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry","volume":"79","author":"Suzuki","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ahj.2013.12.014","article-title":"Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"167","author":"O'Brien","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib73","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ahj.2014.07.002","article-title":"Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"168","author":"O'Brien","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib74","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCULATIONAHA.108.783688","article-title":"Get with the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack","volume":"119","author":"Schwamm","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.09.012_bib75","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.amjcard.2008.08.062","article-title":"Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation","volume":"103","author":"Lewis","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib76","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jacc.2015.05.062","article-title":"Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation","volume":"66","author":"Hess","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib77","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1253\/circj.CJ-14-0144","article-title":"Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry","volume":"78","author":"Okumura","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib78","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1253\/circj.CJ-15-0095","article-title":"Validation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation \u2013 subanalysis of the J-RHYTHM Registry","volume":"79","author":"Tomita","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.amjmed.2016.09.012_bib79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.15-1095","article-title":"Clinical characteristics and outcomes in extreme elderly (age \u226585) Japanese patients with atrial fibrillation: the Fushimi AF Registry","volume":"149","author":"Yamashita","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2016.09.012_bib80","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2015.07.026","article-title":"Age threshold for increased stroke risk among patients with atrial fibrillation","volume":"66","author":"Chao","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2016.09.012_bib81","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"12","author":"Camm","year":"2010","journal-title":"Europace"},{"key":"10.1016\/j.amjmed.2016.09.012_bib82","first-page":"833","article-title":"Differences among western European countries in anticoagulation management of atrial fibrillation: data from the PREFER IN AF Registry","volume":"111","author":"Le Heuzey","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2016.09.012_bib83","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","article-title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry","volume":"128","author":"Steinberg","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2016.09.012_bib84","doi-asserted-by":"crossref","first-page":"e000535","DOI":"10.1161\/JAHA.113.000535","article-title":"Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation","volume":"2","author":"Steinberg","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.amjmed.2016.09.012_bib85","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/CIRCOUTCOMES.114.001303","article-title":"Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"8","author":"Freeman","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjmed.2016.09.012_bib86","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ahj.2014.04.005","article-title":"Outcomes registry for better informed treatment of atrial fibrillation II: rationale and design of the ORBIT-AF II registry","volume":"168","author":"Steinberg","year":"2014","journal-title":"Am Heart J"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293431631018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293431631018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:12:38Z","timestamp":1757581958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293431631018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S000293431631018X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2016.09.012","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2016.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}